August 1, 2017 | Silenseed, an Israeli, clinical-stage bio-pharmaceutical company that develops cancer therapies, is raising $10 million. Founded in 1999 by Amotz Shemi, the company is planning to use the money to fund the second phase of a trial, which was recently approved by the FDA, to develop a pancreatic cancer treatment. Silenseed uses a targeted RNA interference (RNAi) to develop the cancer drugs and delivery systems for treatment.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments